Top Tech Startups to Work For in 2027

Our technology and services help people navigate the stressful, confusing immigration and visa application process. We built our company on a simple idea: never, ever forget that behind all the applications and case files there are people. We truly care about those people — their hopes, their dreams, their fears — and helping them realize what’s possible.

Quince is a new e-commerce Company that is focused on leveraging a M2C (manufacturer to customer) supply chain to deliver premium essentials at the lowest market price. We act as a thin "storefront" to bring manufacturers and artisans closer to their customers through shared partnership in brand/marketing.

Coralogix is a full-stack observability platform that enables businesses to monitor and manage data in real time, providing instant insights without the need for indexing. The platform supports Log Analytics, application performance monitoring (APM), security information and event management (SIEM), real user monitoring (RUM), and infrastructure monitoring, offering complete visibility into AI performance, security, and governance in a single solution. Coralogix offers a simple pricing model based on data volume, along with world-class support that ensures rapid response times and swift resolutions.

The company leverages machine learning, automation, and peptide synthesis to build platforms for science at scale. With its foundations in engineering disciplines, the company’s platforms vertically integrate proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance basic research, target validation, and clinical trials.

Our modular, on-site technology captures climate-changing CO2 from the air, and puts it directly into our customers' production processes. The result is a greener, cleaner and cheaper product that can help their businesses go carbon neutral or even negative.

CoreMap has a patented breakthrough technology for the mapping of atrial fibrillation (AF) to enable a curative therapy. 24m patients suffer from permanent AF with a US healthcare spend of $26b annually. For these patients there are few therapeutic options and a high risk of stroke.